Crigler-Najjar syndrome

Crigler-Najjar syndrome is a severe condition characterized by high levels of a toxic substance called bilirubin in the blood (hyperbilirubinemia). Bilirubin is produced when red blood cells are broken down. This substance is removed from the body only after it undergoes a chemical reaction in the liver, which converts the toxic form of bilirubin (called unconjugated bilirubin) to a nontoxic form called conjugated bilirubin. People with Crigler-Najjar syndrome have a buildup of unconjugated bilirubin in their blood (unconjugated hyperbilirubinemia).

Bilirubin has an orange-yellow tint, and hyperbilirubinemia causes yellowing of the skin and whites of the eyes (jaundice). In Crigler-Najjar syndrome, jaundice is apparent at birth or in infancy. Severe unconjugated hyperbilirubinemia can lead to a condition called kernicterus, which is a form of brain damage caused by the accumulation of unconjugated bilirubin in the brain and nerve tissues. Babies with kernicterus are often extremely tired (lethargic) and may have weak muscle tone (hypotonia). These babies may experience episodes of increased muscle tone (hypertonia) and arching of their backs. Kernicterus can lead to other neurological problems, including involuntary writhing movements of the body (choreoathetosis), hearing problems, or intellectual disability.

Crigler-Najjar syndrome is divided into two types. Type 1 (CN1) is very severe, and affected individuals can die in childhood due to kernicterus, although with proper treatment, they may survive longer. Type 2 (CN2) is less severe. People with CN2 are less likely to develop kernicterus, and most affected individuals survive into adulthood.

Frequency

Crigler-Najjar syndrome is estimated to affect fewer than 1 in 1 million newborns worldwide.

Causes

Mutations in the $UGT1A1$ gene cause Crigler-Najjar syndrome. This gene provides instructions for making the bilirubin uridine diphosphate glucuronosyl transferase (bilirubin-UGT) enzyme, which is found primarily in liver cells and is necessary for the removal of bilirubin from the body.

The bilirubin-UGT enzyme performs a chemical reaction called glucuronidation. During this reaction, the enzyme transfers a compound called glucuronic acid to unconjugated bilirubin, converting it to conjugated bilirubin. Glucuronidation makes bilirubin dissolvable in water so that it can be removed from the body.
Mutations in the *UGT1A1* gene that cause Crigler-Najjar syndrome result in reduced or absent function of the bilirubin-UGT enzyme. People with CN1 have no enzyme function, while people with CN2 have less than 20 percent of normal function. The loss of bilirubin-UGT function decreases glucuronidation of unconjugated bilirubin. This toxic substance then builds up in the body, causing unconjugated hyperbilirubinemia and jaundice.

**Inheritance Pattern**

Crigler-Najjar syndrome is inherited in an autosomal recessive pattern, which means both copies of the *UGT1A1* gene in each cell have mutations. A less severe condition called Gilbert syndrome can occur when one copy of the *UGT1A1* gene has a mutation.

**Other Names for This Condition**

- Crigler Najjar syndrome
- familial nonhemolytic unconjugated hyperbilirubinemia
- hereditary unconjugated hyperbilirubinemia

**Diagnosis & Management**

**Genetic Testing Information**

- What is genetic testing? [primer/testing/genetictesting](https://primer/testing/genetictesting)

**Research Studies from ClinicalTrials.gov**


**Other Diagnosis and Management Resources**


**Additional Information & Resources**

**Health Information from MedlinePlus**

- Encyclopedia: Kernicterus [https://medlineplus.gov/ency/article/007309.htm](https://medlineplus.gov/ency/article/007309.htm)
• Health Topic: Jaundice
  https://medlineplus.gov/jaundice.html

• Health Topic: Liver Diseases
  https://medlineplus.gov/liverdiseases.html

Genetic and Rare Diseases Information Center
• Crigler-Najjar syndrome type 2

• Crigler Najjar syndrome, type 1
  https://rarediseases.info.nih.gov/diseases/47/crigler-najjar-syndrome-type-1

Educational Resources
• Centers for Disease Control and Prevention: Facts About Jaundice and Kernicterus
  https://www.cdc.gov/ncbddd/jaundice/facts.html

• MalaCards: crigler-najjar syndrome, type i
  https://www.malacards.org/card/crigler_najjar_syndrome_type_i

• MalaCards: crigler-najjar syndrome, type ii
  https://www.malacards.org/card/crigler_najjar_syndrome_type_ii

• Orphanet: Crigler-Najjar syndrome
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=205

• Orphanet: Crigler-Najjar syndrome type 1
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=79234

• Orphanet: Crigler-Najjar syndrome type 2
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=79235

Patient Support and Advocacy Resources
• American Liver Foundation
  https://liverfoundation.org/

• National Organization for Rare Disorders (NORD)
  https://rarediseases.org/rare-diseases/crigler-najjar-syndrome/

Scientific Articles on PubMed
• PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28Crigler-Najjar+Syndrome%5BMAJR%5D%29+AND+%28Crigler-Najjar+syndrome%5BTIAB%5D%29+AND+english%5BLa%5D+AND+human%5Bmh%5D+AND+%22last+1800+days%22%5Bdp%5D
Catalog of Genes and Diseases from OMIM

- CRIGLER-NAJJAR SYNDROME, TYPE I
  http://omim.org/entry/218800

- CRIGLER-NAJJAR SYNDROME, TYPE II
  http://omim.org/entry/606785

Sources for This Summary

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12480568

- Servedio V, d’Apolito M, Maiorano N, Minuti B, Torricelli F, Ronchi F, Zancan L, Perrotta S, Vajro P, 
  Boschetto L, Iolascon A. Spectrum of UGT1A1 mutations in Crigler-Najjar (CN) syndrome patients: 

- Sneitz N, Bakker CT, de Knegt RJ, Halley DJ, Finel M, Bosma PJ. Crigler-Najjar syndrome in 
  The Netherlands: identification of four novel UGT1A1 alleles, genotype-phenotype correlation, 
  humu.21133. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19830808

- Udomuksorn W, Elliot DJ, Lewis BC, Mackenzie PI, Yoovathaworn K, Miners JO. Influence of 
  mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation 
  kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet 

Reprinted from Genetics Home Reference:

Reviewed: February 2012
Published: September 10, 2019

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services